3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential

Biotech stocks, namely those involved with gene editing, have been explosive. Just look at CRISPR Therapeutics (NASADQ:CRSP), for example. Since late October, CRSP rocketed from about $40 a share to about $90.18. All thanks to positive US FDA and European Commission rulings on CRISPR’s treatments for sickle cell, and transfusion-dependent beta-thalassemia. Even shares of Beam Therapeutics (NASDAQ:BEAM) soared from about $17 to $32.90. Not only is the company working on a sickle cell treatment of its own, it ...